$8.4 M

IMUN Mkt cap, 31-Oct-2017

$65 K

Immune Therapeutics Revenue Q1, 2018
Immune Therapeutics Gross profit (Q1, 2018)31.8 K
Immune Therapeutics Gross profit margin (Q1, 2018), %49%
Immune Therapeutics Net income (Q1, 2018)-731.9 K
Immune Therapeutics EBIT (Q1, 2018)-988.3 K
Immune Therapeutics Cash, 31-Mar-201830.4 K

Immune Therapeutics Financials

Immune Therapeutics Income Statement

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

16.2 k3.5 k

Revenue growth, %

(79%)

General and administrative expense

71.1 m4.1 m2.7 m3.9 m

Operating expense total

71.1 m4.1 m2.7 m3.9 m

EBIT

(96 m)(45.3 m)(15.8 m)(14.3 m)

EBIT margin, %

(97567%)(412125%)

Interest expense

1.4 m388.2 k271 k3.4 m

Net Income

(106.1 m)(49.9 m)(16.9 m)(19.8 m)

Quarterly

USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q1, 2017Q3, 2017Q1, 2018

Revenue

2.1 k5.6 k5 k3.5 k65 k

Cost of goods sold

33.2 k

Gross profit

31.8 k

Gross profit Margin, %

49%

R&D expense

129.2 k

General and administrative expense

3.7 m901.7 k402 k443.6 k865.3 k939.3 k666.1 k620.9 k638.2 k

Operating expense total

3.7 m901.7 k402 k443.6 k865.3 k939.3 k666.1 k1.4 m1 m

Depreciation and amortization

557

EBIT

(6.5 m)(7.1 m)(2.9 m)(2.5 m)(2.6 m)(5 m)(1.5 m)(1.4 m)(988.3 k)

EBIT margin, %

(139486%)(43405%)(51460%)(143795%)(1520%)

Interest expense

121 k94.1 k18 k50.7 k79.9 k301.4 k575.8 k118.9 k220.5 k

Net Income

(11.2 m)(2.9 m)(2.6 m)(6.6 m)(2.7 m)(1.6 m)(731.9 k)

Immune Therapeutics Balance Sheet

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

406.6 k192 k23.1 k74.4 k

Accounts Receivable

16.2 k

Current Assets

622.5 k222 k39.3 k74.4 k

Total Assets

19.2 m6.1 m41.2 k76.4 k

Accounts Payable

839.9 k2.1 m1.9 m1.8 m

Short-term debt

817.2 k

Current Liabilities

2.4 m3.4 m6 m9.2 m

Long-term debt

817.2 k

Non-Current Liabilities

121.1 k327.5 k

Total Debt

1.6 m

Total Liabilities

2.6 m3.7 m9.2 m

Additional Paid-in Capital

308.1 m338 m343.4 m360.4 m

Retained Earnings

(283 m)(333.5 m)(349.9 m)(365.7 m)

Total Equity

16.6 m2.4 m(9.1 m)

Debt to Equity Ratio

0.1 x

Debt to Assets Ratio

0.1 x

Financial Leverage

1.2 x2.6 x0 x

Quarterly

USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q3, 2017Q1, 2018

Cash

58.7 k58.6 k30.9 k22.4 k153.9 k132.8 k64.3 k22.2 k98.1 k22.6 k30.4 k

Accounts Receivable

2.1 k7.7 k12.7 k19.7 k2.7 k

Inventories

214.3 k158.6 k

Current Assets

93.7 k108.3 k62.9 k60.1 k211.9 k153.4 k78.2 k22.2 k98.1 k236.9 k189 k

Total Assets

17.3 m16.6 m5.7 m5.6 m5.6 m154.8 k79.1 k22.8 k100 k239.9 k193.3 k

Accounts Payable

1.6 m1.8 m1.9 m1.9 m1.9 m1.9 m1.5 m1.5 m1.7 m2.2 m2.4 m

Current Liabilities

4 m2.7 m3.7 m3.9 m4.6 m6.3 m7 m7.5 m10.4 m8.6 m11.4 m

Non-Current Liabilities

71.1 k354.4 k429 k109.3 k

Total Liabilities

8.6 m11.4 m

Additional Paid-in Capital

324.4 m338.4 m339.8 m340.2 m343.9 m351.3 m354.3 m357.4 m361.5 m365.3 m367.2 m

Retained Earnings

(307.3 m)(318.5 m)(336.6 m)(338.8 m)(342.6 m)(354.4 m)(358.3 m)(362.3 m)(368.3 m)(369.4 m)(373.6 m)

Total Equity

13.3 m13.9 m1.7 m1.2 m935.3 k(6.9 m)(7.5 m)(10.3 m)(8.4 m)(11.2 m)

Financial Leverage

1.3 x1.2 x3.4 x4.6 x6 x0 x0 x0 x0 x0 x

Immune Therapeutics Cash Flow

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(106.1 m)(49.9 m)(16.9 m)(19.8 m)

Depreciation and Amortization

1.2 k2.5 k2.6 k1.6 k

Accounts Receivable

(16.2 k)13.5 k

Inventories

246.3 k40 k

Accounts Payable

553.2 k1.8 m900.5 k541 k

Cash From Operating Activities

(3.8 m)(2.8 m)(2.8 m)

Cash From Investing Activities

(58.5 k)

Cash From Financing Activities

3.7 m2.7 m2.9 m

Interest Paid

4.5 k20.5 k29.6 k

Quarterly

USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q1, 2018

Net Income

(11.2 m)(2.9 m)(2.6 m)(6.6 m)(2.7 m)(731.9 k)

Depreciation and Amortization

434

Accounts Receivable

2.1 k7.7 k12.7 k19.7 k2.7 k

Inventories

19.5 k

Accounts Payable

1.6 m1.8 m1.9 m1.9 m1.9 m1.9 m1.5 m1.5 m1.7 m78.2 k

Cash From Operating Activities

(455.8 k)

Cash From Investing Activities

(2 k)

Cash From Financing Activities

473.5 k

Interest Paid

15.2 k
Report incorrect company information